2. Academic Validation
  3. Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners

Development of inhibitors for uPAR: blocking the interaction of uPAR with its partners

  • Drug Discov Today. 2021 Apr;26(4):1076-1085. doi: 10.1016/j.drudis.2021.01.016.
Cai Yuan 1,  Zhanzhi Guo 1,  Shujuan Yu 2,  Longguang Jiang 3,  Mingdong Huang 4
Affiliations

Affiliations

  • 1 College of Biological Science and Engineering, Fuzhou University, Fuzhou, Fujian, 350116, China.
  • 2 College of Chemistry, Fuzhou University, Fujian, 350116, China.
  • 3 College of Chemistry, Fuzhou University, Fujian, 350116, China. Electronic address: [email protected].
  • 4 College of Chemistry, Fuzhou University, Fujian, 350116, China. Electronic address: [email protected].
PMID: 33486111 DOI: 10.1016/j.drudis.2021.01.016
Abstract

Urokinase-type plasminogen activator receptor (uPAR) mediates a multitude of biological activities, has key roles in several clinical indications, including malignancies and inflammation, and, thus, has attracted intensive research over the past few decades. The pleiotropic functions of uPAR can be attributed to its interaction with an array of partners. Many inhibitors have been developed to intervene with the interaction of uPAR with these partners. Here, we review the development of these classes of uPAR inhibitor and their inhibitory mechanisms to promote the translation of these inhibitors to clinical applications.

Figures
Products